Dulaglutide vs Tirzepatide
A side-by-side research comparison of Dulaglutide and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dulaglutide | Tirzepatide |
|---|---|---|
| Full name | Dulaglutide (Trulicity) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Prescription medication (FDA-approved) | FDA Approved |
| Mechanism | Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | ~63,000 Da | 4,814 Da |
| Half-life | ~5 days (supports weekly dosing) | 5 days (120 hours) |
| Bioavailability | ~65% subcutaneous | High (SubQ ~80%) |
| Typical dose | 0.75 mg - 4.5 mg once weekly | 2.5 mg → titrate up to 15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection (pre-filled pen) | Subcutaneous injection |
Dulaglutide reported benefits
- Significant weight loss (3-5% at standard doses)
- Improved glycemic control
- Reduced cardiovascular events (REWIND trial)
- Once-weekly convenience
- Appetite suppression
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.